M
Mary K. Klein
Researcher at University of Rochester
Publications - 21
Citations - 2054
Mary K. Klein is an academic researcher from University of Rochester. The author has contributed to research in topics: Toceranib & Survival analysis. The author has an hindex of 16, co-authored 21 publications receiving 1783 citations.
Papers
More filters
Journal ArticleDOI
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Cheryl A. London,Phyllis B. Malpas,Stacey L. Wood-Follis,Joseph F. Boucher,Anthony Rusk,Mona P. Rosenberg,Carolyn J. Henry,Kathy L. Mitchener,Mary K. Klein,John G. Hintermeister,Philip J. Bergman,Guillermo Couto,Guy N. Mauldin,Gina M. Michels +13 more
TL;DR: Palladia has biological activity against canine MCTs and can be administered on a continuous schedule without need for routine planned treatment breaks, and shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
Journal ArticleDOI
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
Nicholas J. Roberts,Linping Zhang,Filip Janku,Amanda Collins,Ren Yuan Bai,Verena Staedtke,Anthony Rusk,David Tung,Maria Miller,Jeffrey James Roix,Kristen V. Khanna,Ravi Murthy,Robert S. Benjamin,Thorunn Helgason,Ariel D. Szvalb,Justin E. Bird,Sinchita Roy-Chowdhuri,Halle H. Zhang,Yuan Qiao,Baktiar O. Karim,Jennifer S. McDaniel,Amanda K. Elpiner,Alexandra Sahora,Joshua Lachowicz,Brenda Phillips,Avenelle I. Turner,Mary K. Klein,G. S. Post,Luis A. Diaz,Gregory J. Riggins,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Chetan Bettegowda,Chetan Bettegowda,David L. Huso,Mary Varterasian,Saurabh Saha,Shibin Zhou +38 more
TL;DR: Clostridium novyi-NT targets aberrant tumor physiology and can produce a precise, robust, and reproducible antitumor response, and is shown to can precisely eradicate neoplastic tissues in selected patients.
Journal ArticleDOI
Toxicity criteria of the veterinary radiation therapy oncology group.
Tracy A. LaDue,Mary K. Klein +1 more
Journal ArticleDOI
Amputation and Carboplatin for Treatment of Dogs With Osteosarcoma: 48 Cases (1991 to 1993)
Philip J. Bergman,E. Gregory MacEwen,Ilene D. Kurzman,Carolyn J. Henry,A S Hammer,Deborah W. Knapp,Ann Hale,Stephen A. Kruth,Mary K. Klein,Jeffrey S. Klausner,Alan M. Norris,Dudley L. McCaw,Rodney C. Straw,Stephen J. Withrow +13 more
TL;DR: Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2 and Neutropenia was the dose-limiting toxicity in this study.
Journal ArticleDOI
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
Deborah A. Grosenbaugh,A. Timothy Leard,Philip J. Bergman,Mary K. Klein,Karri Meleo,Steven Susaneck,Paul R. Hess,Monika K. Jankowski,Pamela D Jones,Nicole F. Leibman,Maribeth H. Johnson,Ilene D. Kurzman,Jedd D. Wolchok +12 more
TL;DR: Results support the safety and efficacy of the huTyr DNA vaccine in dogs as adjunctive treatment for oral MM and response to DNA vaccination in dogs with oral MM may be useful in development of plasmid DNA vaccination protocols for human patients with similar disease.